P. Cappelli et al., N-3 POLYUNSATURATED FATTY-ACID SUPPLEMENTATION IN CHRONIC PROGRESSIVERENAL-DISEASE, JN. Journal of nephrology, 10(3), 1997, pp. 157-162
Chronic renal failure (CRF) may be accelerated by secondary lipid and
immune abnormalities which could be antagonized by polyunsaturated fat
ty acid (PUFA), We examined 20 CRF patients on conservative treatment,
randomized in two groups: G1 consisted of 10 control patients and G2
10 patients supplemented for 12 months with a 3.4 g daily dose of PUFA
, In basal conditions and after 12 months the following parameters wer
e checked: creatinine clearance (CCr), daily urinary protein excretion
per unit of residual renal function (UProt/CCr), rate of progression
of renal insufficiency (Delta CCr); triglycerides (TG), total(TC), HDL
(HDALC) and LDL (LDLC) cholesterol, apolipoproteins Apo Al, Apo B, li
poprotein(a) Lp(a); lymphocyte subpopulations; spontaneous (c) and sti
mulated (s) cytokines IL-1 beta, IL-2, tumor necrosis factors TNF-alph
a secretion by peripheral mononuclear cells, The groups did not differ
in their basal parameters, which did not change in G1 during follow-u
p, In G2 the following parameters, initially higher than normal signif
icantly decreased after 12 months: TG (2.9 +/- 0.45 to 2.6 +/- 0.3 mmo
l/l p<0.005), Apo B (1.40 +/- 0.37 to 1.22 +/- 0.36 g/l, p<0.05), c TN
F-alpha (1008.1 +/- 534.9 to 726.8 +/- 458.7 pg/ml, p<0.05), Spontaneo
us (c) IL-1 beta (216.7 +/- 116.2 to 150.5 +/- 107.8 pg/ml, p<0.05), c
IL-2 (124.5 +/- 43.8 to 101.6 +/- 25.8 pg/ml, p<0.05), and s TNF-alph
a (2456.4 +/- 908.3 to 1632.2 +/- 497.1 pg/ml, p<0.005) also decreased
, although already within the normal range at baseline, G2 patiens exp
erienced a steady monthly reduction of CCr whereas it rose progressive
ly in G1 (p<0.05), with a simultaneous increase In UProt/CCr (p<0.05).
PUFA are beneficial on the lipid and immune abnormalities secondary t
o CRF and may also have a useful effect on the progression of chronic
renal damage.